Introduction {#sec1_1}
============

Diabetic nephropathy (DN) accounts for a large proportion of the potential cost of diabetes to both individuals and society \[[@B1],[@B2]\]. In many areas such as cardiovasology, cardiac surgery and endocrinology, it is commonly accompanied by acute kidney injury (AKI). AKI concurrent with DN (AKI/DN) can be induced by serious infection, hypertension, hypotension, contrast agents, drugs, surgery and renal venous thrombosis and usually leads to multiple organ failure, high mortality and an extensive burden on patients \[[@B3],[@B4]\]. AKI is not an isolated event, and it involves distant organ injury including the lungs, heart, liver and brain \[[@B4]\]. The prognosis for patients with AKI/DN is poor compared to AKI patients without DN. For critically ill patients, any decrease in renal function could worsen outcome and increase mortality \[[@B5]\] as their condition changes from risk through injury to failure based on the RIFLE (Risk, Injury, Failure, Loss, End Stage renal disease) criteria \[[@B6]\]. The optimal mode of renal replacement therapy (RRT) for such patients is not yet known. Continuous renal replacement therapy (CRRT) is generally used in AKI patients with hemodynamic instability \[[@B7],[@B8]\]. However, despite its widespread use, no definitive studies have shown continuous therapy to be superior or even more hemodynamically pleasing than intermittent hemodialysis (IHD). Therefore, it is important to find the optimal mode of RRT for this population.

Since recently, sustained low-efficiency daily dialysis with hemofiltration (SLEDD-f) is increasingly being used in patients with intensive AKI. The SLEDD-f, a hybrid renal replacement technique, differs from conventional hemodialysis mainly in the length of treatment time (\>8 vs. 4 h) and in blood and dialysate pump velocity (100-200 vs. 200-400 ml/min and 100-300 vs. 500 ml/min, respectively) \[[@B9],[@B10]\]. The hybrid renal replacement technique possesses the advantages of conventional hemodialysis and slow continuous therapies and reduces their inherent limitations, such as high costs and logistics and technical complications \[[@B9],[@B10],[@B11],[@B12]\].

Recent studies have shown that patients treated with high-volume hemofiltration, daily IHD or SLEDD-f demonstrate lower mortality and an improved solute clearance \[[@B13],[@B14],[@B15]\]. However, studies on the application of SLEDD-f in patients with AKI/DN are still limited \[[@B13],[@B16]\]. Until recently, only CRRT was available in our Nephrology Department and medical intensive care unit (ICU). Now SLEDD-f has become an alternative for hemodynamically unstable patients. In this retrospective study, we compared the system coagulation/thrombosis episodes and mortality of patients who were treated only with CRRT and those treated only with SLEDD-f. We also evaluated the cost of CRRT compared to SLEDD-f in AKI/DN patients.

Subjects and Methods {#sec1_2}
====================

All medical records of AKI/DN patients who received either SLEDD-f or CRRT in the Nephrology Department or the medical ICU of our hospital from January 2006 to December 2012 were reviewed. The study was approved by the IRB. The primary indication for these sustained modalities at our institution is hemodynamic instability as defined by the nephrologists Junzhang Cheng and Hong Jiang. Typically, hemodynamically stable patients receive IHD. In order to choose patients with similar characteristics and to minimize confounding, the following inclusion criteria were used: patients clinically diagnosed with DN (Mogensen criterion \[[@B17]\], stage IV), AKI based on the AKI Network criteria \[[@B18]\], an Acute Physiology and Chronic Health Evaluation II (APACHE-II) score \>10 \[[@B19]\], a Sepsis-Related Organ Failure Assessment (SOFA) score \>8 \[[@B20]\] and baseline serum creatinine (SCr) \<5.0 mg/dl (442.0 μmol/l). The exclusion criteria were concomitant malignant tumor, kidney transplant, surgery due to septic shock or baseline SCr \>5.0 mg/dl.

During this period, a total of 154 patients received hemopurification treatment. One hundred and seven of them met the inclusion criteria and of these, 55 received CRRT and 52 received SLEDD-f treatment. All treatments were performed using the Gambro dialysis system. The CRRT and SLEDD-f protocols are described below. The ultrafiltration (UF) rate of the dialysis machine did not exceed the replacement fluid rate controlled by an external pump. Utilization of SLEDD-f was decided only if a qualified nurse was available because it requires a high level of nursing acuity. These treatments were monitored by the ICU nursing staff. Because SLEDD-f is labor-intensive, the nurse-to-patient ratio was maintained at 1:1 rather than that the 1:2 required for conventional CRRT. Except for the RRT, all other care was provided by the medical team in the Nephrology Department or ICU. APACHE-II scores were calculated at the initiation of dialysis as a predictor of mortality. In addition, clinical progression was monitored using the SOFA score and inflammation indices such as procalcitonin (PCT) and white blood cell count. Anticoagulant dosage and cost were also calculated at the baseline and at the end of RRT.

CRRT Protocol {#sec2_1}
-------------

CRRT was performed similar to how it is described below except that the replacement fluid was given after filtration at 3,000 ml/h and a session lasted 20-72 h. Continuous veno-venous hemofiltration was chosen as the CRRT mode for all the patients. The treatments were performed utilizing the Gambro Prismaflex CRRT machine, and a same high-flux filter (Gambro Prisma M100, AN69 membrane).

SLEDD-f Protocol {#sec2_2}
----------------

SLEDD-f was performed using the Gambro AK200 Ultra S dialysis machine and the high-flux dialyzer (Gambro Prisma M100, AN69 membrane). Dialysate was produced online with water passing through a portable carbon tank. The SLEDD-f operating parameters at our institution have been largely standardized. Blood flows were set at 150-200 ml/min and countercurrent dialysate flows were set at 300 ml/min. Replacement fluid was standardized and prefiltrated at 2,000 ml/h. The compositions of the replacement fluid were 140 mEq/l sodium, 2.15 mEq/l calcium, 2.0 mEq/l potassium, 1.0 mEq/l magnesium, 3 mEq/l lactate, 32 mEq/l bicarbonate and 110 mg/dl glucose \[[@B15]\]. Net UF rate was calculated as (replacement fluids + all other fluids in) -- (total UF + all other fluids out) and was usually between 0 and 100 ml/h based on the needs and hemodynamic status of each patient \[[@B15]\]. Serum chemistries were monitored every 6 h. When the serum phosphorus level decreased to \<2.0 mg/dl, sodium phosphate was administered via a peripheral intravenous injection. Time for SLEDD-f was 8-10 h per session. Low-molecular-weight heparin was administrated at 3,000 U bolus followed by 500 U/h after 4 h, and the activated partial thromboplastin time was adjusted to 1.5 times of the control value.

CRRT or SLEDD-f was initiated if patients met one of the following criteria \[[@B21]\]: oliguria (urine output \<200 ml/12 h), anuria (urine output \<50 ml/12 h), severe acidemia (pH \<7.1) due to metabolic acidosis, azotemia (urea \>30 mmol/l), hyperkalemia (K^+^ \>6.5 mmol/l or rapid increases in K^+^), suspected uremic organ involvement (pericarditis/encephalopathy/neuropathy/myopathy), severe dysnatremia (Na^+^ \>160 or \<115 mmol/l), hyperthermia (core temperature \>39.5°C), clinically significant organ edema (especially in the lungs), drug overdose with dialyzable toxin or coagulopathy requiring large amounts of blood products in a patient at risk of pulmonary edema/acute respiratory distress syndrome.

The criteria for renal recovery included: SCr \<1.2 mg/dl, urine output \>800 ml/24 h and no need for RRT.

Statistical Analysis {#sec2_3}
--------------------

Normally distributed variables were expressed as mean values ± SD. Comparison between groups was performed using the SPSS 17.0 software (SPSS Inc., Chicago, Ill., USA), the Student t test, the Mann-Whitney U test (for numerical variables) and the χ^2^ test (for categorical variables). p \< 0.05 was considered significant.

Results {#sec1_3}
=======

Causes of AKI and Clinical Characteristics of Patients {#sec2_4}
------------------------------------------------------

The causes of AKI for patients with DN included infection, biotic factors, heart failure, hypertension and hypotension. No patient underwent noninvasive, assisted ventilation such as bilevel positive airway pressure. Patients in both groups had similar causes of AKI and similar clinical characteristics such as age, basal SCr and number of organs experiencing failure, shown in table [1](#T1){ref-type="table"}. There were no statistical differences in AKI causes, age or other characteristics.

Patient Outcomes {#sec2_5}
----------------

The predicted mortality based on the APACHE-II score varied from 20 to 49% (mean 32.3 ± 6.9%) for patients in the CRRT group and from 18 to 51% (mean 33.8 ± 7.4%) for patients in the SLEDD-f group. The CRRT group had a 30-day survival rate in 89.1% (n = 49) of the patients and a 30-day renal recovery rate in 54.5% (n = 30). For the SLEDD-f group, these rates were 92.3% (n = 48) and 61.5% (n = 32), respectively. The causes of mortality in patients treated with CRRT were septicemia from pneumococcal infection (n = 3) or cardiogenic shock (n = 1), hemorrhage of the digestive tract (n = 1) and myocardial infarction (n = 1). The cause of mortality in the SLEDD-f group was septicemia from pneumococcal infection (n = 2), cardiogenic shock (n = 1) or pancreatitis (n = 1). Some patients were off dialysis 30 days after the initiation of SLEDD-f or CRRT.

Clinical Characteristics and Inflammation Index Changes after RRT {#sec2_6}
-----------------------------------------------------------------

Before treatment, all patients had similar APACHE-II and SOFA scores, renal function, levels of serum blood urea nitrogen and SCr, but after treatment, the APACHE-II and SOFA scores and the serum blood urea nitrogen and SCr had decreased in both groups, as shown in table [2](#T2){ref-type="table"}. In addition, inflammation indices such as C-reactive protein (CRP), high-sensitivity CRP, PCT and white blood cell count had also decreased after CRRT and SLEDD-f treatment. There were no statistical differences between patients in the 2 groups.

RRT Complications and Cost {#sec2_7}
--------------------------

CRRT and SLEDD-f were well tolerated by the AKI/DN patients. Severe intradialytic hypotension did not occur. Metabolic control of electrolytes and acid/base status were excellent in both groups. However, the mean daily operating time for SLEDD-f was 8.8 ± 1.4 h while that of CRRT was 23.5 ± 2.1 h, with the difference being statistically significant (p \< 0.001). RRT times were similar in the 2 groups (9.2 ± 2.4 vs. 8.7 ± 1.3 h). The requirement for anticoagulation was a dose of low-molecular-weight heparin of 6,320 ± 490 U/day for patients treated with SLEDD-f and 15,230 ± 1,460 U/day for patients treated with CRRT; this difference was also statistically significant (p = 0.000). The cost of hemopurification for patients treated with SLEDD-f was USD 1,950 ± 230, significantly less than the USD 4,210 ± 820 for patients treated with CRRT (p \< 0.01). Furthermore, the total expense of hospitalization for patients treated with SLEDD-f was lower than that for patients treated with CRRT (USD 2,900 ± 390 vs. USD 5,710 ± 930, respectively, as shown in fig. [1](#F1){ref-type="fig"}).

Discussion {#sec1_4}
==========

In this study, the mortality and renal recovery rates were similar in the patients treated with CRRT and SLEDD-f, thereby indicating that these treatment modalities have the same effect on AKI/DN patients. The high survival rate was possibly due to timeous hemopurification treatment. Meanwhile, SLEDD-f offered other advantages including a lower heparin dosage, shorter therapy time and lower hospitalization costs than for CRRT. Episodes of technical failure (with the machines) or of compromised care were not observed with either treatment modality. SLEDD or SLEDD-f consists of an adaptation of conventional IHD or hemodiafiltration, aimed to be low efficient. This low efficiency was achieved by decreasing blood and dialysate pump velocity and extending treatment time to reduce hourly fluid removal. In 1999, Schlaeper et al. \[[@B22]\] treated critically ill patients requiring RRT by slow continuous dialysis defined by the following parameters: a blood flow of 100-200 ml/min, a dialysate flow of 100-300 ml/min, the use of a modified hemodialysis machine with controlled UF and online production of bicarbonate-based dialysate, and continuous or extended daily treatment of 8-24 h. This treatment was successful and since then, the role of SLEDD in AKI has gained more and more attention \[[@B9],[@B12],[@B15]\]. In addition, SLEDD has shown good effects in the treatment of critically ill patients or multiple-organ dysfunction syndrome \[[@B10],[@B23],[@B24]\] and acute poisoning \[[@B25],[@B26]\].

Likewise, SLEDD-f has emerged as a predictor for achieving the UF volume initially desired. Moreover, the dialytic efficacy of SLEDD-f reported in the literature is at least comparable to that of continuous therapies using high-dialysate and substitution fluids \[[@B27]\]. Meanwhile, SLEDD-f can alleviate the inflammatory response of AKI/DN patients as well as CRRT can, demonstrated by how serum CRP and PCT both declined after treatment.

Our study also indicated that, compared to continuous therapies, SLEDD-f requires less anticoagulation agent due to a shorter dialytic period. Moreover, the application of SLEDD-f is a protector factor of coagulation. In this study, less hemorrhage occurred during SLEDD-f due to the shorter RRT time and less total heparin being applied; this could have some beneficial impact on patients at a high risk for hemorrhagic complications. The reduced treatment time of SLEDD-f means that at least 2 patients can be treated with the same dialysis monitor within 24 h. Furthermore, unlike with CRRT, it is easy to decide when to switch from SLEDD-f to a conventional IHD.

SLEDD-f is also less costly and involves a smaller workload. Unlike CRRT, the SLEDD-f technique is easy for nurses to learn and use and it requires less monitoring and intervention. Thus, it is more suitable for economically undeveloped areas or areas with a scarcity of health resources. When compared to IHD, to the best of our knowledge, the availability of nursing staff was the only limiting factor for providing SLEDD-f treatment.

Conclusion {#sec1_5}
==========

Our data suggest that SLEDD-f treatment has adequate small solute clearance, significant large solute clearance and excellent clinical, metabolic and economic outcomes in AKI/DN patients. In addition, this treatment can be delivered autonomously in the ICU and other non-nephrology departments by in-house nursing personnel in a similar manner to CRRT. This is logistically attractive to many units, especially in primary hospitals.
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###### 

Causes of AKI/DN and clinical characteristics of patients in the 2 groups

                                            CRRT (n = 55)   SLEDD-f (n = 52)   p value
  ----------------------------------------- --------------- ------------------ ---------
  Causes[^1^](#T1F1){ref-type="table-fn"}                                      
   Infection                                12 (21.8)       11 (21.2)          0.933
   Antibiotics                              13 (23.6)       12 (23.1)          0.946
   Heart failure                            9 (16.4)        8 (15.4)           0.890
   Hypertension or hypotension              2 (3.6)         2 (3.8)            0.954
   Two of the above                         9 (16.4)        10 (19.2)          0.698
   Three or more of the above               10 (18.2)       9 (17.3)           0.906
  Clinical characteristics                                                     
   Age, years                               59.27 ± 6.92    59.83 ± 6.69       0.675
   Basic SCr, μmol/l                        217.5 ± 68.1    215.8 ± 74.0       0.903
   Highest SCr, μmol/l                      690.0 ± 94.0    707.7 ± 85.6       0.312
   Organ failure, n                         1.76 ± 0.69     1.83 ± 0.62        0.620
   Duration of oliguria, days               6.29 ± 1.26     6.69 ± 1.41        0.122

n = Number of organs experiencing failure.

Figures represent the number of patients with the percentage in parentheses.

###### 

Comparison of clinical characteristics and inflammation indexes after RRT

                    CRRT           SLEDD-f                       
  ----------------- -------------- -------------- -------------- --------------
  APACHE-II score   20.5 ± 4.57    13.8 ± 3.5     20.8 ± 3.4     14.6 ± 2.7
  SOFA score        13.3 ± 2.8     7.29 ± 1.51    13.5 ± 2.0     7.35 ± 1.22
  BUN, mmol/l       23.69 ± 2.7    10.57 ± 2.28   23.9 ± 2.2     10.87 ± 1.76
  SCr, μmol/l       690.0 ± 94.0   198.3 ± 37.3   707.7 ± 85.6   206.8 ± 29.4
  CRP, mg/ml        19.8 ± 4.3     5.67 ± 1.32    19.9 ± 4.7     5.51 ± 1.78
  Hs-CRP, mg/l      8.5 ± 1.2      2.35 ± 0.51    8.1 ± 1.5      2.33 ± 0.34
  PCT, ng/ml        1.48 ± 0.73    0.32 ± 0.08    1.61 ± 0.70    0.33 ± 0.10
  WBC, × 10^9^/l    12.5 ± 2.9     6.62 ± 1.35    12.2 ± 2.8     6.93 ± 1.50

BUN = Blood urea nitrogen; Hs-CRP = high-sensitivity CRP; WBC = white blood cell count.
